High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Salivary duct carcinoma (SDC) is an aggressive cancer with no standard treatment.
• Identifying molecular markers is crucial for SDC diagnosis and therapy.

Purpose of the Study:

• To comprehensively analyze DNA aberrations in SDC.
• To identify potential molecular markers for diagnosis and therapy.

Main Methods:

• Next-generation sequencing of 50 cancer genes and copy number variation analysis of 21 genes in 37 SDC patients.
• Fluorescent in situ hybridization to confirm ERBB2 amplification.
• Retrospective review of clinical and histopathological records.

Main Results:

• Genetic alterations found in 78.3% of SDC tumors.
• Common mutations include PIK3CA (24.3%), ERBB2 (10.8%), and EGFR (10.8%).
• ERBB2 mutations are reported for the first time in SDC; ERBB2 amplification is common, often with EGFR and ERBB3 amplification.

Conclusions:

• PIK3CA and/or ERBB2 alterations are implicated in SDC development.
• These alterations may serve as valuable diagnostic tools.
• SDC-associated genetic alterations represent potential therapeutic targets.